Shandong Langnuo Pharmaceutical Co. Ltd.

Primary Objective To compare the absorption rate and extent of utpatinib extended-release tablets (15 mg (C17H19F3N6O)) supplied by Shandong Langnuo Pharmaceutical Co., Ltd. with those of utpatinib extended-release tablets (15 mg (C17H19F3N6O) certified by AbbVie Deutschland GmbH & Co. KG, trade name: RINVOQ) in healthy adults under fasting and postprandial administration conditions, and to evaluate their bioequivalence. Secondary Objective To evaluate the safety of utpatinib extended-release tablets (15 mg (C17H19F3N6O)) supplied by Shandong Langnuo Pharmaceutical Co., Ltd. with those of utpatinib extended-release tablets (15 mg (C17H19F3N6O) certified by AbbVie Deutschland GmbH & Co. KG, trade name: RINVOQ) in healthy adults under fasting and postprandial administration conditions.

Primary Objective: Using BR170720 oral suspension (30 ml, 30 mg) developed by Shandong Biono Pharmaceutical Co., Ltd. as the test formulation (T) and brexpiprazole tablets (trade name: Rexulti®, 2 mg) manufactured by Otsuka Pharmaceutical Co., Ltd. as the reference formulation (R), we investigated the pharmacokinetic parameters of the test and reference formulations after single administration under fasting and fed conditions and evaluated their bioequivalence. Secondary Objective: To evaluate the safety of test formulation T (BR170720 oral suspension, 30 ml, 30 mg, developed by Shandong Biono Pharmaceutical Co., Ltd.) and reference formulation R (brexpiprazole tablets, trade name: Rexulti®, 2 mg, manufactured by Otsuka Pharmaceutical Co., Ltd.) in healthy volunteers.

Primary Objective: Using perampanel fine granules produced by Shandong Langnuo Pharmaceutical Co., Ltd. as the test formulation (T), and perampanel fine granules (trade name: Fycompa®) licensed and produced by Aerosei Co., Ltd. as the reference formulation (R), the pharmacokinetic characteristics of the test and reference formulations after single oral administration in healthy volunteers under fasting and fed conditions were evaluated, and the bioequivalence of the two formulations was assessed. Secondary Objective: Investigate the safety of the test and reference formulations after oral administration in healthy volunteers. Evaluate the palatability of perampanel fine granules in healthy Chinese volunteers to provide a basis for the oral palatability of perampanel fine granules.